表皮生长因子受体酪氨酸激酶抑制剂联合化疗治疗肺癌的研究进展
표피생장인자수체락안산격매억제제연합화료치료폐암적연구진전
Advances in epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment
  • 万方数据
    国际肿瘤学杂志 국제종류학잡지
    JOURNAL OF INTERNATIONAL ONCOLOGY
    2013年 7期 526-529 ,共4页

    张贝贝%宋正波%张沂平

    장패패%송정파%장기평

    受体,表皮生长因子%药物疗法%肺肿瘤 受體,錶皮生長因子%藥物療法%肺腫瘤
    수체,표피생장인자%약물요법%폐종류
    Receptor,epidermal growth factor%Drug therapy%Lung neoplasms
    表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(EGFR-TKI)对EGFR突变肺癌患者表现出很好的疗效,对于EGFR野生型肺癌患者化疗药物是首选,EGFR-TKI和化疗药物联合在基础研究方面表现出良好的协同作用,而在临床研究方面与其两药联合的时序有关.
    표피생장인자수체(EGFR)락안산격매억제제(EGFR-TKI)대EGFR돌변폐암환자표현출흔호적료효,대우EGFR야생형폐암환자화료약물시수선,EGFR-TKI화화료약물연합재기출연구방면표현출량호적협동작용,이재림상연구방면여기량약연합적시서유관.
    Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show good efficacy for the lung cancer patients with EGFR mutations.Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type.In basic research,EGFR-TKIs combination with chemotherapy drugs show good synergy.But in clinical research,the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문